Key result
Hepatokines, including fetuin-A and FGF21, act as endocrine signals regulating systemic metabolism and contribute to the pathogenesis of metabolic syndrome, NAFLD, type 2 diabetes, and CVDs.
Hepatokines play a pivotal role in systemic metabolism and represent potential therapeutic targets for metabolic disorders and cardiovascular diseases.
Hepatokines may refine cardiometabolic risk assessment; extends liver-heart axis understanding but remains hypothesis-generating.
The liver is a central regulator of systemic energy homeostasis and has a pivotal role in glucose and lipid metabolism. Impaired gluconeogenesis and dyslipidemia are often observed in patients with nonalcoholic fatty liver disease (NAFLD). The liver is now recognized to be an endocrine organ that secretes hepatokines, which are proteins that regulate systemic metabolism and energy homeostasis. Hepatokines are known to contribute to the pathogenesis of metabolic syndrome, NAFLD, type 2 diabetes (T2DM), and cardiovascular diseases (CVDs). In this review, we focus on the roles of two major hepatokines, fetuin-A and fibroblast growth factor 21 (FGF21), as well as recently-redefined hepatokines, such as selenoprotein P, angiopoietin-like protein 4 (ANGPTL4), and leukocyte cell-derived chemotaxin 2 (LECT2). We also assess the biology and molecular mechanisms of hepatokines in the context of their potential as therapeutic targets for metabolic disorders and cardiovascular diseases.
No takes yet. Share an insight, caveat, or question.
Jung et al. (2016) conducted a review in Metabolic disorders and cardiovascular diseases. Hepatokines (fetuin-A, FGF21, selenoprotein P, ANGPTL4, LECT2) was evaluated. Hepatokines, including fetuin-A and FGF21, act as endocrine signals regulating systemic metabolism and contribute to the pathogenesis of metabolic syndrome, NAFLD, type 2 diabetes, and CVDs.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: